New Janssen Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease (Johnson & Johnson)

(Source: Johnson & Johnson) 6b013b02-b92b-48fe-a032-f436d13689f0.pdf June 8, 2016 New Janssen Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease Sirukumab One-year Radiographic Data Show Significant Inhibition of Joint Destruction New Janssen Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease Sirukumab One-year Radiographic Data Show Significant Inhibition of Joint Destruction LONDON, June 8, 2016 /PRNewswire/ -- Janssen...